Global Information
회사소개 | 문의 | 위시리스트

비전형 용혈성요독증후군 : 파이프라인 리뷰

Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 08월 상품 코드 321898
페이지 정보 영문 104 Pages
가격
US $ 2,000 ₩ 2,357,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,715,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,072,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


비전형 용혈성요독증후군 : 파이프라인 리뷰 Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2019
발행일 : 2019년 08월 페이지 정보 : 영문 104 Pages

비전형 용혈성요독증후군은 주로 신장 기능에 영향을 미치는 질환으로, 모든 연령대에서 발병합니다. 비정상적인 혈전이 신장의 모세혈관에 형성되며, 복통, 피로, 초조감, 혈뇨 등의 증상이 생깁니다.

비전형 용혈성요독증후군(Atypical Hemolytic Uremic Syndrome) 치료제의 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

목차

서론

비전형 용혈성요독증후군 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

개발중인 치료제 : 기업별

파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품

개발중인 제품 : 기업별

치료제 개발에 참여하고 있는 기업

  • Adienne Pharma & Biotech
  • Alnylam Pharmaceuticals, Inc.
  • ChemoCentryx, Inc.
  • Omeros Corporation

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • ALN-CC5
  • CCX-168
  • ET-006
  • ETR-001
  • Mubodina
  • OMS-72

파이프라인 제품의 최신 동향

개발 휴지중인 프로젝트

부록

도표

KSM 15.01.14

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Achillion Pharmaceuticals Inc, H2 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Akari Therapeutics Plc, H2 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Amgen Inc, H2 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by ChemoCentryx Inc, H2 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Greenovation Biotech GmbH, H2 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Omeros Corp, H2 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Ra Pharmaceuticals Inc, H2 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Dormant Projects, H2 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2019, provides an overview of the Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline landscape.

Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. Symptoms include vomiting, abdominal pain, pale skin tone, fatigue and irritability, blood in the urine and confusion.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1, 3 and 5 respectively.

Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atypical Hemolytic Uremic Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atypical Hemolytic Uremic Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atypical Hemolytic Uremic Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atypical Hemolytic Uremic Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Overview
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Companies Involved in Therapeutics Development
    • Achillion Pharmaceuticals Inc
    • Akari Therapeutics Plc
    • Alexion Pharmaceuticals Inc
    • Amgen Inc
    • ChemoCentryx Inc
    • Greenovation Biotech GmbH
    • Omeros Corp
    • Ra Pharmaceuticals Inc
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Drug Profiles
    • avacopan - Drug Profile
    • AVTS-001 - Drug Profile
    • danicopan - Drug Profile
    • eculizumab biosimilar - Drug Profile
    • GRN-003 - Drug Profile
    • Monoclonal Antibody for Atypical Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
    • narsoplimab - Drug Profile
    • nomacopan - Drug Profile
    • ravulizumab - Drug Profile
    • ravulizumab next generation - Drug Profile
    • Small Molecules to Inhibit MASP2 for Immunology - Drug Profile
    • zilucoplan - Drug Profile
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Dormant Projects
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Discontinued Products
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q